ITOS – iteos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $31.00 to $19.00. They now have an "overweight" rating on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
iTeos to Participate in Upcoming Investor Conferences
Form 4 iTeos Therapeutics, Inc. For: Dec 06 Filed by: Feltquate David
Form SC 13G iTeos Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Form 4 iTeos Therapeutics, Inc. For: Nov 19 Filed by: Gall Matthew
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: Boxer Capital Management, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.